CommercialCoverageMedium impact
07.06.03c, Bioimpedance for the Detection of Lymphedema
Independence Blue Cross·PA · Oncology, Physical Therapy, General Surgery +2 more·Medical Policy
Effective date
Nov 17, 2025
We identified it
Sep 3, 2026
Summary
Independence Blue Cross has changed bioimpedance spectroscopy (CPT 93702) coverage status from Experimental/Investigational to Medically Necessary for lymphedema detection and surveillance, effective November 17, 2025. Billing teams must now process claims for this service when medical necessity criteria are met, specifically for asymptomatic patients with lymphatic system trauma/surgery/radiotherapy or symptomatic patients after conservative therapy failure.
Action Required
By November 17, 2025: Billing team must update claims processing system to change CPT 93702 from non-covered/experimental status to covered status for Independence Blue Cross Commercial plans. Update claim submission rules to include required ICD-10 diagnosis codes I89.0 and I97.2 for claim adjudication. Ensure providers document medical necessity in patient records before billing, including: (1) confirmation of asymptomatic status with surgery/radiotherapy/trauma history OR symptomatic status post-conservative therapy, and (2) evidence that testing guides clinical decision-making for intervention. Create internal audit checklist to verify documentation requirements are met before claim submission. Failure to include proper medical necessity documentation will result in claim denials.